Madrigal Pharmaceuticals, Inc. (MDGL)

Market Cap	6.73B
Revenue (ttm)	76.81M
Net Income (ttm)	-518.67M
Shares Out	21.81M
EPS (ttm)	-25.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	682,034
Open	294.00
Previous Close	293.41
Day's Range	293.00 - 312.52
52-Week Range	168.25 - 368.29
Beta	-0.40
Analysts	Buy
Price Target	347.33 (+12.61%)
Earnings Date	Oct 31, 2024

About MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 376
• Stock Exchange: NASDAQ
• Ticker Symbol: MDGL
• Website: https://www.madrigalpharma.com

Analyst Forecast

According to 14 analysts, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is $347.33, which is an increase of 12.61% from the latest price.

Price Target

$347.33

(12.61% upside)

Analyst Consensus: Buy